Neogenomics (NEO) Enterprise Value (2010 - 2026)

Neogenomics (NEO) has reported Enterprise Value for 17 consecutive years, with $1.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 121.47% year-over-year to $1.7 billion; the trailing twelve-month figure through Jun 2026 stood at $1.7 billion (up 121.47% YoY), and the FY2025 full-year result was $1.4 billion, down 21.32% from the prior year.
• Enterprise Value rose to $1.7 billion in Q2 2026 per NEO's latest filing, from $815.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at $1.8 billion in Q1 2023 and bottomed at $558.3 million in Q2 2022.
• Historically, Enterprise Value has averaged $1.2 billion across 5 years, with a median of $1.3 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value tumbled 88.77% in 2022, then jumped 192.63% in 2023.
• Over 5 years, Enterprise Value stood at $734.7 million in 2022, then surged by 123.99% to $1.6 billion in 2023, then increased by 4.82% to $1.7 billion in 2024, then retreated by 21.32% to $1.4 billion in 2025, then climbed by 26.78% to $1.7 billion in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $1.7 billion, $815.9 million, and $1.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.